You want to join a clinical trial. Here’s what to know about the hurdles.

The Gap Between Wanting a Trial and Actually Getting One

Earthguardiansonline.com – For millions of Americans living with chronic illness, the idea of enrolling in a clinical trial carries real weight. A recent online survey polling more than 2,000 adults found that 71% of respondents managing chronic conditions said they would likely step into a trial if the opportunity arose. Yet the same group revealed a startling disconnect: roughly two-thirds had never once been asked by their own doctor whether a trial might suit them. Older data from 2020 painted an even bleaker picture, showing that only 9% of adults had ever received an invitation to participate in any kind of clinical study.

The numbers behind the scenes are just as sobering. Industry estimates suggest that as many as 86% of trials fail to fill their enrollment quotas within the planned study window. That shortfall delays drug approvals, stretches budgets, and ultimately slows the pipeline of new therapies reaching patients who need them.

Why Enrollment Falters

Even when a patient identifies a trial that appears to match their condition, a cascade of practical obstacles can derail participation. Geographic distance from a study site, the cost of travel and lodging, lost wages during visits, and the sheer time commitment of repeated appointments all compound the difficulty. Alan Balch, executive board chair of the Patient Advocate Foundation — an organization that maintains a clinical trial search tool and a library of patient-education materials — frames the problem in blunt terms:

“Recruitment is one thing — retention is another. Every touchpoint is an opportunity for access and affordability to be a problem.”

That language captures a reality many patients face: the moment a trial requires a three-hour drive, a missed workday, or an out-of-pocket copay, the decision to continue can unravel.

What Trials Actually Test

Public understanding of clinical research often narrows to a single image: one group receives an experimental drug, another gets a sugar pill. In practice, the landscape is far broader. Studies evaluate novel therapeutics, combinations of existing medications, medical devices, preventive interventions such as vaccines, behavioral and lifestyle modifications, and new methods for screening or diagnosing disease. For patients confronting terminal or severely debilitating conditions, enrollment can represent the single best available chance at extending life or preserving function.

Mark Fleury, policy principal for emerging science at the American Cancer Society Cancer Action Network, underscores the stakes involved:

“Cancer is often a fatal disease, and clinical trials offer an opportunity to try something that may or may not be better. If you know the existing standard of care has an average survival of eight months, you want something with a better opportunity.”

Advocates also note that even participants assigned to a control arm receive intensified monitoring and what is considered the gold standard of care — a level of attention many patients would not otherwise receive outside a study protocol.

A Personal Stake in the Science

Not every participant is motivated solely by personal medical need. Jim Taylor, whose wife Geri was diagnosed with Alzheimer’s disease in 2012 and died of the condition two years ago, now serves as a public advocate for those navigating the disease. He is currently enrolled in three observational Alzheimer’s studies that use cognitive testing and neuroimaging to document how his own brain changes over time relative to cohorts already diagnosed with the disease.

“The reason I’ve done it is so I can explain to people, with some authenticness and experience, what a trial is like.”

Taylor’s participation illustrates how lived experience and scientific contribution can intersect, giving patients a voice in shaping how research is communicated to the broader public.

Washington Moves to Lower the Barriers

The urgency of improving trial access has drawn fresh federal attention. In June, the Department of Health and Human Services launched an initiative aimed at streamlining and strengthening clinical research infrastructure across the United States. Among its components was a public request for information examining whether existing federal rules — which currently discourage some sponsors from reimbursing participants for travel, lodging, and related expenses — should be modified.

The following month, nearly 200 patient-advocacy and public-health organizations delivered a joint letter to the Senate sponsors of the Clinical Trial Modernization Act, pressing for its passage. The proposed legislation would permit trial sponsors to cover participants’ medical costs, including insurance deductibles and copays, as well as nonmedical expenses such as transportation and childcare. It would also shield up to $2,000 in trial-related financial support from federal taxation, ensuring that enrollment does not jeopardize a participant’s eligibility for Medicaid or other income-based assistance programs.

What a Patient Can Do Today

While legislative and regulatory changes work through their timelines, individuals who wish to explore trial options have concrete steps available now. Asking a treating physician directly about ongoing studies relevant to one’s diagnosis is the most immediate action. National registries and patient-advocacy organizations maintain searchable databases that filter trials by condition, location, and phase. Understanding the specific design of a study — whether it is interventional or observational, what endpoints it tracks, and what follow-up visits entail — helps patients weigh the time and logistical commitments honestly before committing.

The infrastructure of clinical research exists to translate laboratory findings into therapies that reach real patients. Closing the gap between a patient’s willingness to contribute and the system’s ability to accommodate that contribution remains, by every measurable indicator, the defining challenge of the next decade in medical science.